Millennium’s Velcade was granted priority review from the FDA for patients with newly diagnosed multiple myeloma (MM). The sNDA for this indication included data from the Phase III VISTA study, a large, international trial, comparing a Velcade based regimen to a traditional standard of care. Priority review is granted for a treatment that addresses an unmet medical need and demonstrates an improvement over existing therapies. The FDA expedites the approval process for these applications from ...